Navigation Links
Double Helix Consulting Enhances its Strategic Product Commercialization Services with Appointment of Michael Rizzo as Vice President
Date:11/10/2009

NEW YORK, Nov. 10 /PRNewswire/ -- Double Helix Consulting US, a division of London-based Double Helix Development Group, today announced the appointment of Michael Rizzo to the position of Vice President. Rizzo joins a multidisciplinary team of highly experienced strategic pricing, reimbursement and market access consultants with extensive experience across the healthcare industry, which provides product commercialization services to firms in the pharmaceutical, biotechnology and medical device industries. DHC US provides services spanning the product lifecycle, including the following:

(Photo: http://www.newscom.com/cgi-bin/prnh/20091110/NY08977 )

(Logo: http://www.newscom.com/cgi-bin/prnh/20090330/NY91277LOGO )

  • Market opportunity assessment and entry strategy
  • New product planning
  • Product value message development and testing
  • Stakeholder influence mapping and engagement strategy
  • Managed markets strategy
  • Pricing and reimbursement research and planning
  • Mock formulary committee and reimbursement negotiation simulation
  • Health technology assessment and comparative effectiveness research preparation
  • Post-launch market access surveillance and lifecycle management

Drew Baker, President of Double Helix Consulting US, commented, "Mike complements our international market access, pricing and reimbursement capabilities through his vast experience in planning and implementing product development and launch strategies for the US market. His intimate knowledge of managed care market structure, formulary management, contracting strategies, and marketing communications strengthens Double Helix's ability to meet our clients' commercial objectives in the increasingly cost-conscious and value-driven US market."

Chief Executive Officer of Double Helix Development Group, Dr. Wayne Phillips, added, "Double Helix Consulting offers a premier set of services to assist our clients in optimizing product commercialization by enhancing market access through a truly global team of professionals with deep experience from industry, consulting, academia and healthcare authorities. As an example, we have assisted many of our clients with anticipating and generating the evidence needed to elucidate to payers the clinical and economic value associated with new medical technologies. Mike's experience in product planning and launch strategy bolsters our expanding capabilities."

Rizzo joins Double Helix Consulting from Campbell Alliance's managed markets practice where he led client engagements in stakeholder and access risk assessment, value proposition development and messaging, pricing and contracting strategy, product positioning, pull-through, and training. He brings extensive experience in assessing the impact of payers, physicians, patients, and intermediaries on pricing, access, and reimbursement for small molecule and specialty products in the US market. Rizzo's therapeutic expertise is broad including oncology, neurosciences, inflammatory disease, cardiometabolic disease, infectious disease, and women's health. He also worked with Charles River Associates' pharmaceuticals practice, the Pharmaceutical Research and Manufacturers Association (PhRMA), the Lombardi Cancer Research Center at Georgetown University, and The Institute for Genomic Research (TIGR). He holds an MBA from the College of William and Mary, a Master's of Public Policy from Georgetown University, and a BS in Biology from James Madison University.

    Contact:
    Andrew M. Baker
    President
    Double Helix Consulting US
    295 Madison Avenue, 12th Floor
    New York, NY 10017
    [T] 1.646.652.8506  [E] dbaker@dhelixc.com
    www.doublehelixdevelopment.com

Copyright © 2009 Double Helix Development US, Inc.

SOURCE Double Helix Consulting


'/>"/>
SOURCE Double Helix Consulting
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
2. Chinas Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals
3. Global Biofuels Growth to Double by 2015
4. Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production
5. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
6. Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products
7. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
8. Nanoparticles double their chances of getting into sticky situations
9. Carbon nanotube avalanche process nearly doubles current
10. SleepQuest Compliance Again Doubles Industry Average
11. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis Market ... (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, ... is expected to reach USD 2.20 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:12/8/2016)... ... December 08, 2016 , ... From wearable devices ... taking over sports. On Thursday, December 15th a panel of entrepreneurs, innovators and ... playing field at a Smart Talk session. Smart Talk will run from 8:30 ...
(Date:12/8/2016)... BELLINGHAM, Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... neural circuits with very high precision light to control cells — optogenetics — ... brain. In the current state of the art, spatially patterned light projected via ...
(Date:12/8/2016)... ... 2016 , ... KBioBox llc announced today the launch of ... a sophisticated “3 click” gene dditing off target analysis program and a “3 ... https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, pharmaceutical researchers ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/6/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, and the Prison Entrepreneurship ... year funding commitment by Securus to PEP and ... reentry support to more inmates and their families. ... Prison Entrepreneurship Program (PEP) is an independent 501(c)(3) ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):